US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
US6696407B1
(en)
|
1997-03-21 |
2004-02-24 |
The Regents Of The University Of California |
Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
|
GB9726339D0
(en)
|
1997-12-13 |
1998-02-11 |
Zeneca Ltd |
Human-derived tissue-specific potassium channel
|
US6077851A
(en)
*
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
SE9801474D0
(sv)
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
RS51019B
(sr)
|
1999-10-25 |
2010-10-31 |
Active Biotech Ab. |
Lekovi za lečenje malignih tumora
|
EP1365794A2
(en)
|
2000-07-21 |
2003-12-03 |
Lue, Tom |
Prevention and treatment of sexual arousal disorders
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
JP2006502104A
(ja)
*
|
2002-06-25 |
2006-01-19 |
メルク フロスト カナダ アンド カンパニー |
8−(ビアリール)キノリンpde4阻害剤
|
US20070292461A1
(en)
|
2003-08-04 |
2007-12-20 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
WO2005000244A2
(en)
|
2003-06-25 |
2005-01-06 |
Elan Pharmaceuticals, Inc. |
Methods and compositions for treating rheumatoid arthritis
|
US8795693B2
(en)
|
2003-08-04 |
2014-08-05 |
Foamix Ltd. |
Compositions with modulating agents
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
US20060004019A1
(en)
|
2004-04-01 |
2006-01-05 |
Ivan Lieberburg |
Steroid sparing agents and methods of using same
|
WO2006029036A2
(en)
|
2004-09-02 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
DK1797109T3
(en)
|
2004-09-09 |
2016-04-11 |
Yeda Res & Dev |
MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
|
US20060205822A1
(en)
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
US20060276393A1
(en)
|
2005-01-13 |
2006-12-07 |
Sirtris Pharmaceuticals, Inc. |
Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
|
EP1902034B1
(en)
|
2005-06-02 |
2011-03-30 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
WO2007142667A2
(en)
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
CN107176923A
(zh)
|
2005-10-19 |
2017-09-19 |
泰华制药工业有限公司 |
拉奎尼莫钠晶体及其制备方法
|
SI1951674T1
(sl)
|
2005-10-26 |
2012-01-31 |
Merck Serono Sa |
Derivati sulfonamida in njihova uporaba za moduliranje metaloproteinaz
|
US20080108641A1
(en)
|
2006-02-08 |
2008-05-08 |
Ajami Alfred M |
Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
|
US8367629B2
(en)
|
2006-02-14 |
2013-02-05 |
Noxxon Pharma Ag |
MCP-1 binding nucleic acids and use thereof
|
JP2009531304A
(ja)
|
2006-02-28 |
2009-09-03 |
エラン ファーマシューティカルズ,インコーポレイテッド |
α−4阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
|
ES2752137T3
(es)
|
2006-02-28 |
2020-04-03 |
Biogen Ma Inc |
Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
|
EP1991267B1
(en)
|
2006-03-03 |
2017-12-20 |
Biogen MA Inc. |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
US20070218062A1
(en)
|
2006-03-16 |
2007-09-20 |
Genentech, Inc. |
Methods of treating lupus using CD4 antibodies
|
EP2010214A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
UA96449C2
(en)
|
2006-06-12 |
2011-11-10 |
Тева Фармасьютикл Индастриз, Лтд. |
Stable laquinimod preparations
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
RU2009105179A
(ru)
|
2006-07-17 |
2010-08-27 |
Новартис АГ (CH) |
Сульфониламинокарбонилпроизводные амидов холевой кислоты для применения в качестве иммуномодуляторов
|
EP1886996A1
(en)
|
2006-08-10 |
2008-02-13 |
Ferrer Internacional, S.A. |
1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
|
WO2008021368A2
(en)
|
2006-08-11 |
2008-02-21 |
The Johns Hopkins University |
Compositions and methods for neuroprotection
|
EP2392320A1
(en)
|
2006-08-17 |
2011-12-07 |
University Of Chicago |
Treatment of inflammatory diseases
|
WO2008085484A2
(en)
|
2006-12-28 |
2008-07-17 |
Jacobus Pharmaceutical Company, Inc. |
Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
|
WO2009009529A1
(en)
|
2007-07-11 |
2009-01-15 |
Medicinova, Inc. |
Treatment of progressive neurodegenerative disease with ibudilast
|
EP2214657A1
(en)
|
2007-10-23 |
2010-08-11 |
UCB Pharma GmbH |
Compounds for treating demyelination conditions
|
PL2234485T3
(pl)
|
2007-12-20 |
2014-06-30 |
Teva Pharma |
Stabilne preparaty lakwinimodu
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
MX2011002033A
(es)
|
2008-09-03 |
2011-05-02 |
Teva Pharma |
2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基-雜環化合物
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
BR112012000568A2
(pt)
|
2009-06-19 |
2015-10-06 |
Teva Pharma |
tratamento da esclerose múltipla com laquinimod
|
CA2769623A1
(en)
*
|
2009-07-30 |
2011-02-03 |
Teva Pharmaceutical Industries Ltd. |
Treatment of crohn's disease with laquinimod
|
ES2586843T3
(es)
|
2009-08-10 |
2016-10-19 |
Teva Pharmaceutical Industries Ltd. |
Tratamiento de trastornos relacionados con BDNF usando laquinimod
|
DE102010026879A1
(de)
*
|
2010-02-11 |
2011-08-11 |
AMW GmbH, 83627 |
Transdermales System mit Immunmodulator
|
CN105796556A
(zh)
|
2010-03-03 |
2016-07-27 |
泰华制药工业有限公司 |
用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
|
PE20130613A1
(es)
|
2010-03-03 |
2013-06-23 |
Teva Pharma |
Tratamiento de lupus nefritis usando laquinimod
|
EP2542080B1
(en)
|
2010-03-03 |
2016-08-31 |
Teva Pharmaceutical Industries Ltd. |
Treatment of lupus arthritis using laquinimod
|
AU2011274502A1
(en)
|
2010-07-09 |
2013-02-28 |
Teva Pharmaceutical Industries Ltd. |
5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
|
CA2804986A1
(en)
|
2010-07-09 |
2012-01-12 |
Teva Pharmaceutical Industries Ltd. |
Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
|
CA2820586A1
(en)
|
2010-12-07 |
2012-06-14 |
Teva Pharmaceutical Industries Ltd. |
Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
|
CA2830027C
(en)
|
2011-03-31 |
2016-04-26 |
Pfizer Inc. |
Novel bicyclic pyridinones
|
CN103781354A
(zh)
|
2011-07-28 |
2014-05-07 |
泰华制药工业有限公司 |
用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
|
KR20140054129A
(ko)
|
2011-07-28 |
2014-05-08 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라퀴니모드와 인터페론-베타의 병용에 의한 다발성 경화증의 치료
|
SG11201401330YA
(en)
|
2011-10-12 |
2014-05-29 |
Teva Pharma |
Treatment of multiple sclerosis with combination of laquinimod and fingolimod
|
EP2744498A4
(en)
|
2012-02-16 |
2014-12-03 |
Teva Pharma |
N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
AR090885A1
(es)
|
2012-05-02 |
2014-12-10 |
Teva Pharma |
Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
|
TW201350467A
(zh)
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺
|
TW201400117A
(zh)
|
2012-06-05 |
2014-01-01 |
Teva Pharma |
使用拉喹莫德治療眼發炎疾病
|
US20130345257A1
(en)
|
2012-06-26 |
2013-12-26 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型1(cb1)媒介之疾病之拉喹莫德(laquinimod)
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
|
EP2961406A4
(en)
|
2012-10-12 |
2017-01-04 |
Teva Pharmaceutical Industries Ltd. |
Laquinimod for reducing thalamic damage in multiple sclerosis
|
US8975279B2
(en)
|
2012-11-07 |
2015-03-10 |
Teva Pharmaceutical Industries, Ltd. |
Amine salts of laquinimod
|
CA2900503A1
(en)
|
2013-02-15 |
2014-08-21 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with laquinimod
|
JP2016513665A
(ja)
|
2013-03-14 |
2016-05-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラキニモドの経皮製剤
|
EP2970129A2
(en)
|
2013-03-14 |
2016-01-20 |
Teva Pharmaceutical Industries Ltd. |
Crystals of laquinimod sodium and improved process for the manufacture thereof
|
WO2015109083A1
(en)
*
|
2014-01-17 |
2015-07-23 |
Teva Pharmaceutical Industries Ltd. |
Treatment of crohn's disease using low doses of laquinimod
|